DIAGNOS Announces Exercise of Stock Warrants and Provides a Cash Update
February 26 2021 - 1:33PM
Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture:
ADK) (OTCQB: DGNOF), a leader in early detection of critical health
issues through the use of its FLAIRE platform based on Artificial
Intelligence (AI), announces the exercise of 5,076,922 stock
warrants within the past five months. The cash position of the
Corporation as of today is $1,433,000.
In the coming weeks, the Corporation expects to
submit a first claim for disbursement under a financing agreement
in the form of an interest-free loan of up to $2,000,000 from the
government of Québec to support global commercialization. The
financing agreement was initially announced on
September 8th, 2020.
The Corporation is also announcing a grant of
1,200,000 stock options to one of its directors. Stock options vest
at 50% per year, commencing with the first anniversary of the
grant. The exercise price of these stock options has been
established at $0.56 per share. The expiry date to which these
stock options can be exercised has been fixed to
February 24, 2026.
All monies quoted in this press release shall be
stated and paid in lawful money of Canada.
About DIAGNOS
DIAGNOS is a publicly-traded Canadian
corporation with a mission of early detection of critical health
issues through the use of its Artificial Intelligence (“AI”) tool
CARA (Computer Assisted Retina Analysis). CARA is a
tele-ophthalmology platform that integrates with existing equipment
(hardware and software) and processes at the point of care. CARA’s
Artificial Intelligence image enhancement algorithms make standard
retinal images sharper, clearer and easier to read. CARA is
accessible securely over the internet, and is compatible with all
recognized image formats and brands of fundus cameras, and is EMR
compatible. CARA is a cost-effective tool for screening large
numbers of patients in real-time. CARA complies with local
regulations, is FDA cleared for commercialization in the United
States of America, is Health Canada licensed for commercialization
in Canada and is CE marking compliant in Europe.
Additional information is available at
www.diagnos.com and www.sedar.com.
This news release contains forward-looking information. There
can be no assurance that forward-looking information will prove to
be accurate, as actual results and future events could differ
materially from those anticipated in these statements. DIAGNOS
disclaims any intention or obligation to publically update or
revise any forward-looking information, whether as a result of new
information, future events or otherwise. The forward-looking
information contained in this news release is expressly qualified
by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450-678-8882 ext. 224
alarente@diagnos.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024